HONGKONG, May 5, 2026 – CIC extends our warmest congratulations to Starsportmed (01609. HK) on its successful listing on the Hong Kong Stock Exchange (HKEX) today.
CIC's Collaborative Journey to the Listing
Throughout the listing process, CIC provided end-to end support to the company and its sponsors:
Drafted and Compiled the industry overview chapter of the prospectus, laying a solid research foundation for the formal listing application.
Assisted in responding to inquiries from regulatory authorities, ensuring comprehensive and accurate disclosure.
Refined listing application materials continuously to meet stringent market and regulatory requirements.
Under the global offering, Starsportmed offered 8,421,900 H-shares at a final offer price of HK$98.5 per share, raising a total of approximately HK$830 million, with net proceeds of approximately HK$758.4 million after deducting issuance expenses. The Hong Kong public offering was oversubscribed by 7,823.13 times, while the international offering was oversubscribed by 10.41 times. The company introduced four renowned cornerstone investors including JSC International, OrbiMed Asia IV, and Greater Bay Area Development Fund Management, which collectively subscribed for approximately US$37 million (around HK$290 million), accounting for about 34.71% of the offered shares. Starsportmed’s shares opened at HK$288.00 per share, surging 192.39%, valuing the company at HK$15.791 billion.
As a leading domestic player in sports medicine, Starsportmed has disrupted the long-standing dominance of international giants in the sector, setting another benchmark for “Intelligent Manufacturing in China” in high-end medical devices.
According to CIC Reports, China’s sports medicine implants and devices market is still in an early development stage. It is projected to grow from RMB5.4 billion in 2024 to RMB12.1 billion in 2030, representing a CAGR of 14.3%. Historically controlled by international players, four of the top five market participants in 2024 were foreign companies, collectively holding approximately 59.3% market share. Starsportmed ranked fourth in China’s sports medicine implants and devices market in 2024 with a 6.5% share, leading all domestic brands. In the sports medicine implants segment, it held an 8.8% share, ranking first among domestic players and fourth overall; in surgical equipment and consumables, it held a 3.2% share, ranking first among domestic players and sixth overall.
Starsportmed has built four core technology platforms through forward-looking R&D layout: Biomaterials Platform, Imaging & Power Platform, Smart Healthcare Platform, and Tissue Engineering Platform. Leveraging these platforms, it has developed cutting-edge products including wireless medical endoscopic camera systems, arthroscopic surgical robots, and ligament repair scaffolds based on high-purity type I collagen, establishing a platform-driven product matrix capability. As of April 2026, the company owned 27 Class III medical device registration certificates and 25 Class II certificates, the largest number among domestic sports medicine enterprises, underscoring its strong R&D capabilities and high competitive barriers under stringent industry regulation.
The rise of domestic sports medicine device companies represented by Starsportmed breaks import dependence through core technological breakthroughs, which is vital to the self-reliance and high-quality development of China’s high-end medical device industry. Starsportmed’s successful listing opens a new chapter in its international capital operations and will further accelerate technological progress and domestic substitution in China’s sports medicine industry.
As a seasoned Industry Consultant, CIC offers services such as market sizing, competitive analysis, and enterprise value verification, etc., with global experience in advising "first-in-sector" IPOs in healthcare technology sector.
From from IPO preparation to listing hearings, CIC unearths the true intrinsic value of enterprises and translates it into actionable insights for successful capital market landing. Prior to Starsportmed, CIC has supported leading enterprises in successful listings both domestically and overseas, including United Imaging Healthcare, MGI Tech, Contec Medical, Viatom Technology, Lepu Medical, and MicroPort NeuroTech.
About CIC
CIC is a professional consulting firm offering tailored end-to-end support across the full investment and financing lifecycle. The firm boasts a world-leading track record in guiding landmark first-in-sector IPOs across global markets, alongside unrivaled reach and in-depth coverage capabilities across specialized niche market segments.
CIC helps enterprises refine scalable business models and craft compelling capital narratives to enable seamless access to global capital markets, while serving as a trusted due diligence partner to investment institutions. It delivers granular industry insights and direct access to subject matter experts, empowering clients to identify high-value opportunities and mitigate critical risks effectively.
Media Contact
